VEGF, one of the most well-characterized angiogenic factors, stimulates tumor angiogenesis by promoting endothelial cell proliferation and migration,[1] thereby playing a critical role in cancer invasion and metastasis.[2] Bevacizumab, an anti-VEGF monoclonal antibody is increasingly utilized to treat advanced malignancy, while effective in inhibiting tumor vascularization and growth, it also significantly disrupts normal wound healing, a process heavily reliant on angiogenesis.[3]. The gene discussed is VEGFA; the disease is cancer.